• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

antibiotic-resistant bacteria

Biotech

ContraFect halts phase 3 after antimicrobial fails futility test

The inability of the direct lytic agent to beat placebo triggered the stoppage of the study and the cratering of the biotech’s share price.
Nick Paul Taylor Jul 14, 2022 10:35am

Stopping DNA 'packet' exchange could halt bacterial resistance

Jun 14, 2022 8:30am

Lack of policy, investment stifling antibiotics pipeline

Apr 12, 2022 9:00am

Big Pharma-backed AMR Action Fund picks 1st biotech investments

Apr 4, 2022 10:25am

BD joins Day Zero's $21M funding for genomics-based diagnostics

Feb 10, 2022 11:26am

Entasis antibiotic beats last resort treatment in phase 3 trial

Oct 19, 2021 10:35am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy